Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 2/20 | 0.61 |
| ▸ | ARG2 | P78540 | 4/20 | 0.55 |
| ▸ | ARG1 | P05089 | 3/20 | 0.55 |
| ▸ | DDAH1 | O94760 | 2/20 | 0.50 |
| ▸ | OTC | P00480 | 1/20 | 0.49 |
| ▸ | NOS2 | P35228 | 5/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.48 |
| ▸ | NOS1 | P29475 | 3/20 | 0.48 |
| ▸ | NOS3 | P29474 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
| ▸ | APEX1 | P27695 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | GRM8 | O00222 | 1/20 | 0.48 |
| ▸ | GRM6 | O15303 | 1/20 | 0.48 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.48 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.48 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6757882 | 0.92 | GSR (0.77) | GSRARG2ARG1DDAH1OTC | |
| SCHEMBL6316203 | 0.92 | GSR (0.70) | GSRARG2ARG1DDAH1CYP1A2 | |
| SCHEMBL19952877 | 0.92 | GSR (0.70) | GSRARG2ARG1DDAH1CYP1A2 | |
| SCHEMBL31612943 | 0.92 | GSR (0.53) | GSRARG2ARG1DDAH1OTC | |
| SCHEMBL448753 | 0.92 | GSR (0.77) | GSRARG2ARG1DDAH1OTC | |
| SCHEMBL25227671 | 0.90 | GSR (0.52) | GSRARG2ARG1DDAH1NOS2 | |
| SCHEMBL22976016 | 0.90 | GSR (0.74) | GSRARG2ARG1NOS2CYP1A2 | |
| SCHEMBL21131222 | 0.90 | GSR (0.74) | GSRARG2ARG1NOS2CYP1A2 | |
| SCHEMBL9362560 | 0.90 | GRIK1 (0.56) | GSRARG2ARG1DDAH1TSHR | |
| SCHEMBL2263983 | 0.90 | GSR (0.55) | GSRARG2ARG1DDAH1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260041714-A1 | CROSS-LINKING AGENTS AND ASSOCIATED METHODS | UNIV UTAH RES FOUND (US) | 2026-02-12 | — | — | US | disclosed |
| US-12544400-B2 | Treatment of myopic progression | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2026-02-10 | — | — | US | disclosed |
| CN-118234482-A | Treatment of myopia | 犹他大学研究基金会 | 2024-06-21 | — | — | CN | disclosed |
| US-20240122974-A1 | TREATMENT OF MYOPIA | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2024-04-18 | — | — | US | disclosed |
| EP-4324454-A2 | CROSS-LINKING AGENTS AND ASSOCIATED METHODS | University of Utah Research Foundation (US) | 2024-02-21 | — | — | EP | disclosed |
| EP-4291163-A1 | TREATMENT OF MYOPIA | University of Utah Research Foundation (US) | 2023-12-20 | — | — | EP | disclosed |
| EP-3426262-B1 | CROSS-LINKING AGENTS AND ASSOCIATED METHODS | UNIV UTAH RES FOUND (US) | 2023-08-23 | — | — | EP | disclosed |
| US-20230256012-A1 | TREATMENT OF MYOPIC PROGRESSION | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2023-08-17 | — | — | US | disclosed |
| US-20230173142-A1 | BALLISTIC DELIVERY TO MULTILAYERED TISSUES AND RELATED PARTICLES, COMPOSITIONS, METHODS AND SYSTEMS | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2023-06-08 | — | — | US | disclosed |
| US-11524032-B2 | Treatment of myopic progression | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2022-12-13 | — | — | US | disclosed |
| US-20220288114-A1 | MULTI-AGENT OCULAR FORMULATIONS AND TREATMENT METHODS | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2022-09-15 | — | — | US | disclosed |
| WO-2022174094-A1 | TREATMENT OF MYOPIA | AMBATI BALAMURALI (US) | 2022-08-18 | — | — | WO | disclosed |
| EP-3996644-A1 | MULTI-AGENT OCULAR FORMULATIONS AND TREATMENT METHODS | University of Utah Research Foundation (US) | 2022-05-18 | — | — | EP | disclosed |
| CN-114364355-A | Multi-dose ophthalmic formulations and methods of treatment | 犹他大学研究基金会 | 2022-04-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260041714-A1 | CROSS-LINKING AGENTS AND ASSOCIATED METHODS | KCNK17, KCNJ2, KCNK2 | GSR 3412/4885ARG2 3866/4885ARG1 3062/4885 |
| US-12544400-B2 | Treatment of myopic progression | LOXL1, LOXL3, LOXL2 | GSR 2351/4885ARG2 557/4885ARG1 110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.